Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q4 2024 Earnings ... oral medication has sort of primary care broad use kinds of applications being prioritized.

Eli Lilly and Company LLY will release its fourth-quarter financial results, before the opening bell, on Thursday, Feb. 6, 2025. Analysts expect the Indianapolis, Indiana-based company to report ...

Health-care companies rose after strong earnings from one obesity-drug maker. Eli Lilly shares rose after it reiterated its forecast for 32% 2025 revenue growth, amid rising demand for its ...

David Ricks; Chairman of the Board, President, Chief Executive Officer; Eli Lilly and Co Lucas Montarce; Executive Vice President and Chief Financial Officer; Eli Lilly and Co Daniel Skovronsky ...

Comments: Growth in the quarter was driven by Mounjaro, with sales up 60% to $3.5 billion, and Zepbound, with sales of $1.9 billion. New Products revenue, which consists of Ebglyss, Jaypirca, Kisunla, ...

Growth Products revenue increased 13% to $5.95 billion, driven by growth in Verzenio and Jardiance, partially offset by lower Trulicity sales. Also Read: FDA Approves Expanded Use Of Eli Lilly’s ...

Higher volumes of drugs like Mounjaro, Zepbound, Verzenio, Jardiance and Taltz were partially offset by lower sales of Trulicity. Lilly’s new products also contributed to sales growth.

Eli Lilly (NYSE:LLY) on Thursday reported its Q4 ... Meanwhile, sales from Type 2 diabetes medication Trulicity fell ~25% YoY to $1.3B amid competitive headwinds and lower prices.

Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, ...

Eli Lilly And Co (NYSE ... Zepbound sales reached $1.26 billion. Trulicity sales fell 22% to $1.30 billion. GLP-1 diabetes sales increased by 12%, and Obesity care sales increased by 91%.

Eli Lilly’s latest TV ad, unveiled during the Grammys on Sunday night, highlights the importance of early diagnosis for ...